List view / Grid view
The Cabenuva (cabotegravir + rilpivirine) injectable regime could benefit individuals…
The Cabenuva (cabotegravir + rilpivirine) injectable regime could benefit individuals with HIV who have challenges adhering to treatment, Phase III interim analysis suggests.
In this article, European Pharmaceutical Review’s Hannah Balfour explores some…
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
The highest doses of the novel maturation inhibitor, GSK3640254, had…
The highest doses of the novel maturation inhibitor, GSK3640254, had the greatest antiviral activity and were shown to be safe in 34 treatment-naïve adults with HIV.
A novel formulation for dolutegravir has been developed to improve…
A novel formulation for dolutegravir has been developed to improve HIV treatment options for children. Dr Kimberly Smith from ViiV Healthcare discusses the benefits of this new dispersible tablet.
